ScripPhase I data for Merck & Co. Inc. 's BACE1 inhibitor, verubecestat, were published earlier this week in Science Translational Medicine (STM) , spurring headlines that the first successful Alzheime
ScripDevelopment-stage life science company Cardax has named former Novartis, Bristol-Myers Squibb (BMS) and Boehringer Ingelheim (BI) employees as independent members of its board of directors. They are:
ScripLexington, Massachusetts-based startup Alzheon raised an undisclosed amount of private capital from two unidentified private investors to develop ALZ-801, a prodrug of the well-known Alzheimer's drug
ScripJanssen Pharmaceuticals has acquired rights to a series of oral inhibitors of the beta-site amyloid precursor protein-cleaving enzyme (BACE) in preclinical development for Alzheimer's disease at the J